BromSite (0.075% bromfenac ophthalmic solution) / Sun Pharma, Nicox - LARVOL DELTA

A Comparison of the Clinical and Cost-Effectiveness of Multi-Drop Versus Separate Postoperative Drop Use after Cataract Surgery (ASCRS-ASOA 2022) - "Methods This was a retrospective chart review comparing the outcomes after cataract surgery of patients (n=52) who used a Multidrop (containing moxifloxacin, Bromsite, and Predforte) QID for 2 weeks then BID for 2 weeks versus patients who used separate postop drops (n=52); these patients were on ofloxacin QID for 1 week and prednisolone acetate 1% TID for 10 days, then BID for 10 days, then QD for 10 days and Bromsite QD for 3 weeks...Most were due to rebound iritis after stopping drops; 1 patient in the multidrop group had 1+ cell and fibrin at 1 week so was switched to Durezol...The multidrop treatment costs $40 per eye whereas the separate drop treatment $125 on average per surgery. Patient costs may be lower and compliance higher with the multidrop option."

Clinical • HEOR • Cataract • Immunology • Infectious Disease • Inflammation • Macular Edema • Ocular Inflammation • Ophthalmology • Pain • Uveitis

A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. (PubMed, Br J Ophthalmol) - "Dextenza, INVELTYS, Dexycu and Bromsite are examples of DDS that have enjoyed success in clinical trials leading to FDA approval. Nanoparticles and ocular iontophoresis form the next wave of DDS that have the potential to replace topical steroids eye-drops as the treatment of choice for anterior segment inflammation. With the current relentless pace of ophthalmic drug delivery research, the pursuit of a new standard of treatment that eliminates the problems of low bioavailability and patient compliance may soon be realised."

Clinical • Journal • Review • Cataract • Complement-mediated Rare Disorders • Glaucoma • Immunology • Inflammation • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis

InSite Vision reports fourth quarter and full-year 2012 financial results (Businesswire) - P3, N=240; NCT01576952; "Results from the Phase 3 clinical study are expected in the first quarter of 2013."

Anticipated P3 data • Pain

InSite Vision to host Research and Development Conference Call and Webcast on January 9, 2014 (Businesswire) - "InSite Vision Incorporated today announced that the company will host a web-based meeting on Thursday, January 9, 2014 at 10:00 a.m. PT / 1:00 p.m. ET to review the company’s late-stage product development pipeline, recent Phase 3 clinical trial results and 2014 regulatory plans....Timothy Ruane, Chief Executive Officer, will lead the call to discuss InSite’s Phase 3 ophthalmic product development programs, including BromSite....Kamran Hosseini, M.D., Ph.D., Chief Medical Officer, will review recent data from its two Phase 3 trials for BromSite..."

Anticipated P3 data • Pain

Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study. (PubMed, Ophthalmol Ther) - P1/2; "Similar outcomes were observed for subjects using Bromfenac 0.075% in DuraSite® in the BID and QD dosing regimens for the treatment of post-cataract surgery inflammation."

Journal • Biosimilar • CNS Disorders • Immunology • Ophthalmology • Ophthalmology KOL Master Report • Pain

Advances in drug delivery: Less is more (Healio) - "We have gone from the days of finally having a topical NSAID eye drop to now having it as a once-daily brominated formulation with greater potency (Prolensa, Bausch + Lomb; BromSite, Sun Pharmaceuticals), from the days of finally having an ester topical steroid (Lotemax suspension, Bausch + Lomb) to now having submicron- and nano-formulations of the same with greater aqueous penetration (Lotemax SM, Bausch + Lomb; Inveltys, Kala), from the days of hourly topical steroid prednisolone dosing to now having emulsion formulations (Durezol, Novartis) with greater potency and lower dosing."

Online posting

Comparative study finds cataract surgery patients favor simpler medication regimen (Ophthalmology Times) - "At the ASCRS-ASOA annual meeting, being held May 3-7 at the Convention Center in San Diego, CA, Helga P. Sandoval, MD, presented interim results from the study that she is conducting with Kerry Solomon, MD, to compare the use of the compounded drop containing prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac 0.075% (Pred-Gati-Brom LessDrops, Imprimis Rx) with its individual components."

Video: CME rates lower with Omidria, topical NSAID combination (Healio) - "At the Kiawah Eye meeting here, Keith Walter, MD, discusses a study he presented at the American Society of Cataract and Refractive Surgery meeting showing the combination of Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution, Omeros) with topical bromfenac in cataract surgery significantly lowered the rates of cystoid macular edema."

Video